Elanco Animal Health Q2 Earnings Call Highlights

Impact · against what's priced in

Elanco shares are likely to see a positive re-rating following a comprehensive beat across Q2 guidance and an upward revision of the full-year outlook. The growth is driven by successful pet-health launches like Zenrelia and Credelio Quattro, alongside an improved leverage target, though upside for Befrena is capped by supply constraints until 2027.

ELAN+0.70

No priced-in read yet

In context

The company beat the high end of Q2 guidance, raised its full-year organic revenue growth outlook to 6%-7%, and lowered its year-end net leverage target to approximately 3x.

Read from the article alone

• guidance▲12%
• revenue growth
• earnings
• pharmaceuticals
• ELAN
• agriculture
• animal health
• debt reduction
• pet health